Resonance Health Ltd. Stock Analysis RHT.AX

Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. The firm is engaged in the development and commercialization of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. Its segments include software-as-medical-device (SaMD), Corporate, Resonance Clinical, and TrialsWest. Its SaMD products incorporate such as Artificial Intelligence (AI) FerriScan, FerriSmart, HepaFatScan, HepaFatSmar, LiverSmart, and CardiacT2. FerriScan is a core-lab product that provides an accurate assessment of liver iron concentration (LIC) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. The company operates as the Clinical Trial Research Organisation (CRO) and local sponsor for a major global pharma company's clinical trial in Australia of a new drug compound.